{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:37:32Z","timestamp":1791351452598,"version":"4.3.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K09534"],"award-info":[{"award-number":["21K09534"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004721","name":"The University of Tokyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>While the prognosis of patients with cancer has improved, the time burden of treatment has recently been recognized as time toxicity; although, the actual clinical situation remains largely unexplored. This retrospective study aimed to elucidate the time toxicity of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with B-cell lymphoma and the factors influencing it.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We used a nationwide hospital-based database between January 2010 and November 2021 in Japan. We extracted the claims data of patients with diffuse large B-cell lymphoma and follicular lymphoma who were hospitalized and\/or visited hospitals for chemotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among the 7760 R-CHOP administered to 2006 patients, the rate of outpatient therapy increased over time (2010\u20132015: 17.9%; 2016\u20132021: 31.8%). In 2016, the median length of hospitalization was the shortest at 13 days (IQR 8\u201319), which coincided with the peak use of pegylated granulocyte colony-stimulating factor (Peg-G-CSF) during hospitalization in 2015\u20132016, likely driven by changes in the insurance system. In multivariate analysis, the factors associated with longer hospital stays were older age and poor activities of daily living, whereas the use of Peg-G-CSF, a reduced-dose regimen, and treatment at cancer-designated hospitals were associated with shorter stays.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The time toxicity of R-CHOP has improved and may be influenced by the patient\u2019s condition, adequate supportive care, changes in the insurance system, and center-specific treatment proficiency.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00520-025-09335-7","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T01:37:09Z","timestamp":1742261829000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Temporal trends in time toxicity of R-CHOP: a nationwide hospital-based database analysis in Japan"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1162-9010","authenticated-orcid":false,"given":"Hiroaki","family":"Araie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohisa","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimasa","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kadowaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"issue":"4","key":"9335_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235\u2013242. https:\/\/doi.org\/10.1056\/NEJMoa011795","journal-title":"N Engl J Med"},{"issue":"11","key":"9335_CR2","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","volume":"12","author":"M Pfreundschuh","year":"2011","unstructured":"Pfreundschuh M, Kuhnt E, Tr\u00fcmper L, \u00d6sterborg A, Trneny M, Shepherd L et al (2011) CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 12(11):1013\u20131022. https:\/\/doi.org\/10.1016\/S1470-2045(11)70235-2","journal-title":"Lancet Oncol"},{"key":"9335_CR3","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/1471-2407-11-404","volume":"11","author":"KL Cooper","year":"2011","unstructured":"Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 11:404. https:\/\/doi.org\/10.1186\/1471-2407-11-404","journal-title":"BMC Cancer"},{"issue":"9","key":"9335_CR4","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1182\/bloodadvances.2021004665","volume":"5","author":"EJ Bataillard","year":"2021","unstructured":"Bataillard EJ, Cheah CY, Maurer MJ, Khurana A, Eyre TA, El-Galaly TC (2021) Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review. Blood Adv 5(9):2426\u20132437. https:\/\/doi.org\/10.1182\/bloodadvances.2021004665","journal-title":"Blood Adv"},{"issue":"5","key":"9335_CR5","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","volume":"12","author":"F Peyrade","year":"2011","unstructured":"Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S et al (2011) Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre single-arm phase 2 trial. Lancet Oncol 12(5):460\u2013468. https:\/\/doi.org\/10.1016\/S1470-2045(11)70069-9","journal-title":"Lancet Oncol"},{"issue":"3","key":"9335_CR6","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/s10147-015-0912-6","volume":"21","author":"F Iioka","year":"2016","unstructured":"Iioka F, Izumi K, Kamoda Y, Akasaka T, Ohno H (2016) Outcomes of very elderly patients with aggressive B-cell non-Hodgkin lymphoma treated with reduced-dose chemotherapy. Int J Clin Oncol 21(3):498\u2013505. https:\/\/doi.org\/10.1007\/s10147-015-0912-6","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"9335_CR7","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/ajh.27151","volume":"99","author":"D Al-Sarayfi","year":"2024","unstructured":"Al-Sarayfi D, Brink M, Chamuleau MED, Brouwer R, van Rijn RS, Issa D et al (2024) R-miniCHOP versus R-CHOP in elderly patients with diffuse large B-cell lymphoma: a propensity matched population-based study. Am J Hematol 99(2):216\u2013222. https:\/\/doi.org\/10.1002\/ajh.27151","journal-title":"Am J Hematol"},{"key":"9335_CR8","doi-asserted-by":"publisher","first-page":"9817606","DOI":"10.1155\/2016\/9817606","volume":"2016","author":"D Nolasco-Medina","year":"2016","unstructured":"Nolasco-Medina D, Reynoso-Noveron N, Mohar-Betancourt A, Aviles-Salas A, Garc\u00eda-Perez O, Candelaria M (2016) Comparison of three chemotherapy regimens in elderly patients with diffuse large B cell lymphoma: experience at a single national reference center in Mexico. BioMed Res Int 2016:9817606. https:\/\/doi.org\/10.1155\/2016\/9817606","journal-title":"BioMed Res Int"},{"issue":"1","key":"9335_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jgo.2019.07.025","volume":"11","author":"VA Morrison","year":"2020","unstructured":"Morrison VA, Hamilton L, Ogbonnaya A, Raju A, Hennenfent K, Galaznik A (2020) Treatment approaches for older and oldest patients with diffuse large B-cell lymphoma - use of non-R-CHOP alternative therapies and impact of comorbidities on treatment choices and outcome: a Humedica database retrospective cohort analysis, 2007\u20132015. J Geriatr Oncol 11(1):41\u201354. https:\/\/doi.org\/10.1016\/j.jgo.2019.07.025","journal-title":"J Geriatr Oncol"},{"issue":"2","key":"9335_CR10","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/onco.13610","volume":"26","author":"M Di","year":"2021","unstructured":"Di M, Huntington SF, Olszewski AJ (2021) Challenges and opportunities in the management of diffuse large B-cell lymphoma in older patients. Oncologist 26(2):120\u2013132. https:\/\/doi.org\/10.1002\/onco.13610","journal-title":"Oncologist"},{"issue":"1","key":"9335_CR11","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41416-021-01525-4","volume":"126","author":"L Hounsome","year":"2022","unstructured":"Hounsome L, Eyre TA, Ireland R, Hodson A, Walewska R, Ardeshna K et al (2022) Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year real world data of practice patterns and outcomes in England. Br J Cancer 126(1):134\u2013143. https:\/\/doi.org\/10.1038\/s41416-021-01525-4","journal-title":"Br J Cancer"},{"issue":"15","key":"9335_CR12","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/JCO.21.02810","volume":"40","author":"A Gupta","year":"2022","unstructured":"Gupta A, Eisenhauer EA, Booth CM (2022) The time toxicity of cancer treatment. J Clin Oncol 40(15):1611\u20131615. https:\/\/doi.org\/10.1200\/JCO.21.02810","journal-title":"J Clin Oncol"},{"issue":"10","key":"9335_CR13","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1080\/10428194.2024.2352086","volume":"65","author":"M Di","year":"2024","unstructured":"Di M, Su CT, Cowan AJ, Gopal AK, Banerjee R (2024) Mitigating time toxicity in lymphoma and multiple myeloma. Leuk Lymphoma. 65(10):1418\u20131429. https:\/\/doi.org\/10.1080\/10428194.2024.2352086","journal-title":"Leuk Lymphoma."},{"issue":"5","key":"9335_CR14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00520-024-08487-2","volume":"32","author":"PL Quinn","year":"2024","unstructured":"Quinn PL, Saiyed S, Hannon C, Sarna A, Waterman BL, Cloyd JM et al (2024) Reporting time toxicity in prospective cancer clinical trials: a scoping review. Support Care Cancer 32(5):275. https:\/\/doi.org\/10.1007\/s00520-024-08487-2","journal-title":"Support Care Cancer"},{"key":"9335_CR15","doi-asserted-by":"publisher","unstructured":"Banerjee R, Cowan AJ, Ortega M, Missimer C, Carpenter PA, Oshima MU, et al (2024) Financial toxicity, time toxicity, and quality of life in multiple myeloma. Clin Lymphoma Myeloma Leuk 24(7):446\u2013454.e3.e443. https:\/\/doi.org\/10.1016\/j.clml.2024.02.013","DOI":"10.1016\/j.clml.2024.02.013"},{"issue":"3","key":"9335_CR16","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00520-011-1306-6","volume":"20","author":"R Pettengell","year":"2012","unstructured":"Pettengell R, Johnsen HE, Lugtenburg PJ, Silvestre AS, D\u00fchrsen U, Rossi FG et al (2012) Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma. Support Care Cancer 20(3):647\u2013652. https:\/\/doi.org\/10.1007\/s00520-011-1306-6","journal-title":"Support Care Cancer"},{"issue":"10","key":"9335_CR17","first-page":"674","volume":"70","author":"T Tachi","year":"2015","unstructured":"Tachi T, Yasuda M, Usui K, Umeda M, Nagaya K, Osawa T et al (2015) Risk factors for developing infusion reaction after rituximab administration in patients with B-cell non-Hodgkin\u2019s lymphoma. Pharmazie 70(10):674\u2013677","journal-title":"Pharmazie"},{"issue":"7","key":"9335_CR18","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/jjco\/hyac056","volume":"52","author":"K Miyazaki","year":"2022","unstructured":"Miyazaki K (2022) Management of elderly patients with malignant lymphoma. Jpn J Clin Oncol 52(7):690\u2013699. https:\/\/doi.org\/10.1093\/jjco\/hyac056","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"9335_CR19","first-page":"165","volume":"72","author":"MW van der Poel","year":"2014","unstructured":"van der Poel MW, Mulder WJ, Ossenkoppele GJ, Maartense E, Wijermans P, Hoogendoorn M, Schouten HC (2014) Comorbidity and treatment decision-making in elderly non-Hodgkin\u2019s lymphoma patients: a survey among haematologists. Neth J Med 72(3):165\u2013169","journal-title":"Neth J Med"},{"issue":"1","key":"9335_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3960\/jslrt.56.43","volume":"56","author":"Y Naito","year":"2016","unstructured":"Naito Y, Sasaki H, Takamatsu Y, Kiyomi F, Tamura K (2016) Retrospective analysis of treatment outcomes and geriatric assessment in elderly malignant lymphoma patients. J Clin Exp Hematop 56(1):43\u201349. https:\/\/doi.org\/10.3960\/jslrt.56.43","journal-title":"J Clin Exp Hematop"},{"issue":"9","key":"9335_CR21","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1007\/s00520-013-1793-8","volume":"21","author":"B Yanez","year":"2013","unstructured":"Yanez B, Garcia SF, Victorson D, Salsman JM (2013) Distress among young adult cancer survivors: a cohort study. Support Care Cancer 21(9):2403\u20132408. https:\/\/doi.org\/10.1007\/s00520-013-1793-8","journal-title":"Support Care Cancer"},{"key":"9335_CR22","doi-asserted-by":"publisher","unstructured":"Ebi H, Bando H (2019) Precision oncology and the universal health coverage system in Japan. JCO Precis Oncol 3. https:\/\/doi.org\/10.1200\/PO.19.00291","DOI":"10.1200\/PO.19.00291"},{"issue":"8","key":"9335_CR23","doi-asserted-by":"publisher","first-page":"e0237509","DOI":"10.1371\/journal.pone.0237509","volume":"15","author":"S Tsutsu\u00e9","year":"2020","unstructured":"Tsutsu\u00e9 S, Tobinai K, Yi J, Crawford B (2020) Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B-cell lymphoma. PLOS ONE 15(8):e0237509. https:\/\/doi.org\/10.1371\/journal.pone.0237509","journal-title":"PLOS ONE"},{"issue":"10","key":"9335_CR24","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1080\/03007995.2019.1619543","volume":"35","author":"A Mori","year":"2019","unstructured":"Mori A, Hashimoto K, Koroki Y, Wu DBC, Masumori N (2019) The correlation between metastasis-free survival and overall survival in non-metastatic castration resistant prostate cancer patients from the Medical Data Vision claims database in Japan. Curr Med Res Opin 35(10):1745\u20131750. https:\/\/doi.org\/10.1080\/03007995.2019.1619543","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"9335_CR25","doi-asserted-by":"publisher","first-page":"76","DOI":"10.37737\/ace.1.3_76","volume":"1","author":"H Yasunaga","year":"2019","unstructured":"Yasunaga H (2019) Chapter II the diagnosis procedure combination database. Ann Clin Epidemiol Real World Data Japan 1(3):76\u201379","journal-title":"Ann Clin Epidemiol Real World Data Japan"},{"issue":"4","key":"9335_CR26","doi-asserted-by":"publisher","first-page":"e046681","DOI":"10.1136\/bmjopen-2020-046681","volume":"11","author":"T Morishima","year":"2021","unstructured":"Morishima T, Sato A, Nakata K, Matsumoto Y, Koeda N, Shimada H et al (2021) Barthel index-based functional status as a prognostic factor in young and middle-aged adults with newly diagnosed gastric, colorectal and lung cancer: a multicentre retrospective cohort study. BMJ Open 11(4):e046681. https:\/\/doi.org\/10.1136\/bmjopen-2020-046681","journal-title":"BMJ Open"},{"issue":"4","key":"9335_CR27","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/hon.2524","volume":"36","author":"T Hara","year":"2018","unstructured":"Hara T, Yoshikawa T, Goto H, Sawada M, Yamada T, Fukuno K et al (2018) R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: a randomized, open-label, noninferiority phase 3 trial. Hematol Oncol 36(4):638\u2013644. https:\/\/doi.org\/10.1002\/hon.2524","journal-title":"Hematol Oncol"},{"key":"9335_CR28","doi-asserted-by":"publisher","unstructured":"Walewski J, Paszkiewicz-Kozik E, Michalski W, Rymkiewicz G, Szpila T, Butrym A, et al. (2020) First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4. Br J Haematol. 188(6):898\u2013906. https:\/\/doi.org\/10.1111\/bjh.16264","DOI":"10.1111\/bjh.16264"},{"issue":"1","key":"9335_CR29","first-page":"1","volume":"15","author":"K Tokunaga","year":"1991","unstructured":"Tokunaga K, Matsuzawa Y, Kotani K, Keno Y, Kobatake T, Fujioka S, Tarui S (1991) Ideal body weight estimated from the body mass index with the lowest morbidity. Int J Obes 15(1):1\u20135","journal-title":"Int J Obes"},{"issue":"6","key":"9335_CR30","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P et al (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173(6):676\u2013682. https:\/\/doi.org\/10.1093\/aje\/kwq433","journal-title":"Am J Epidemiol"},{"issue":"6","key":"9335_CR31","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/j.dsx.2020.10.022","volume":"14","author":"RA TutyKuswardhani","year":"2020","unstructured":"TutyKuswardhani RA, Henrina J, Pranata R, Anthonius Lim M, Lawrensia S, Suastika K (2020) Charlson comorbidity index and a composite of poor outcomes in COVID-19 patients: a systematic review and meta-analysis. Diabetes Metab Syndr 14(6):2103\u20132109. https:\/\/doi.org\/10.1016\/j.dsx.2020.10.022","journal-title":"Diabetes Metab Syndr"},{"issue":"33","key":"9335_CR32","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1200\/JCO.2016.67.2980","volume":"34","author":"S Cortelazzo","year":"2016","unstructured":"Cortelazzo S, Tarella C, Gianni AM, Ladetto M, Barbui AM, Rossi A et al (2016) Randomized trial comparing R-CHOP versus high-dose sequential chemotherapy in high-risk patients with diffuse large B-cell lymphomas. J Clin Oncol 34(33):4015\u20134022. https:\/\/doi.org\/10.1200\/JCO.2016.67.2980","journal-title":"J Clin Oncol"},{"issue":"33","key":"9335_CR33","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.2217\/fon-2021-0400","volume":"17","author":"S Tsutsu\u00e9","year":"2021","unstructured":"Tsutsu\u00e9 S, Makita S, Yi J, Crawford B (2021) Economic burden in treated Japanese patients with relapsed\/refractory large B-cell lymphoma. Future Oncol 17(33):4511\u20134525. https:\/\/doi.org\/10.2217\/fon-2021-0400","journal-title":"Future Oncol"},{"issue":"5","key":"9335_CR34","doi-asserted-by":"publisher","first-page":"e0269169","DOI":"10.1371\/journal.pone.0269169","volume":"17","author":"S Tsutsu\u00e9","year":"2022","unstructured":"Tsutsu\u00e9 S, Makita S, Yi J, Crawford B (2022) Cost drivers associated with diffuse large B-cell lymphoma (DLBCL) in Japan: a structural equation model (SEM) analysis. PLOS ONE 17(5):e0269169. https:\/\/doi.org\/10.1371\/journal.pone.0269169","journal-title":"PLOS ONE"},{"issue":"6","key":"9335_CR35","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s10147-024-02504-4","volume":"29","author":"T Yoshinami","year":"2024","unstructured":"Yoshinami T, Nozawa K, Yokoe T, Ozaki Y, Nishio H, Tsuchihashi K et al (2024) Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022. Int J Clin Oncol 29(6):681\u2013688. https:\/\/doi.org\/10.1007\/s10147-024-02504-4","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"9335_CR36","doi-asserted-by":"publisher","first-page":"e060390","DOI":"10.1136\/bmjopen-2021-060390","volume":"12","author":"S Yamaguchi","year":"2022","unstructured":"Yamaguchi S, Okada A, Sunaga S, Ikeda Kurakawa K, Yamauchi T, Nangaku M et al (2022) Impact of COVID-19 pandemic on healthcare service use for non-COVID-19 patients in Japan: retrospective cohort study. BMJ Open 12(4):e060390. https:\/\/doi.org\/10.1136\/bmjopen-2021-060390","journal-title":"BMJ Open"},{"issue":"15","key":"9335_CR37","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","volume":"368","author":"K Dunleavy","year":"2013","unstructured":"Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J et al (2013) Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 368(15):1408\u20131416. https:\/\/doi.org\/10.1056\/NEJMoa1214561","journal-title":"N Engl J Med"},{"issue":"4","key":"9335_CR38","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1200\/JCO.2013.49.7586","volume":"32","author":"PA Fields","year":"2014","unstructured":"Fields PA, Townsend W, Webb A, Counsell N, Pocock C, Smith P et al (2014) De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial. J Clin Oncol 32(4):282\u2013287. https:\/\/doi.org\/10.1200\/JCO.2013.49.7586","journal-title":"J Clin Oncol"},{"key":"9335_CR39","doi-asserted-by":"publisher","first-page":"103377","DOI":"10.1016\/j.critrevonc.2021.103377","volume":"163","author":"C Visco","year":"2021","unstructured":"Visco C, Pregnolato F, Ferrarini I, De Marco B, Bonuomo V, Sbis\u00e0 E et al (2021) Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: a systematic review and single-arm metanalysis. Crit Rev Oncol Hematol 163:103377. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103377","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"9335_CR40","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S2352-3026(19)30051-1","volume":"6","author":"PP Xu","year":"2019","unstructured":"Xu PP, Fu D, Li JY, Hu JD, Wang X, Zhou JF et al (2019) Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial. Lancet Haematol 6(6):e328\u2013e337. https:\/\/doi.org\/10.1016\/S2352-3026(19)30051-1","journal-title":"Lancet Haematol"},{"issue":"18","key":"9335_CR41","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.2169\/internalmedicine.8291-16","volume":"56","author":"H Araie","year":"2017","unstructured":"Araie H, Sakamaki I, Matsuda Y, Tai K, Ikegaya S, Itoh K et al (2017) 3A Comparison between R-THP-COP and R-CHOP regimens for the treatment of diffuse large B-cell lymphoma in old patients: a single-institution analysis. Intern Med 56(18):2407\u20132413. https:\/\/doi.org\/10.2169\/internalmedicine.8291-16","journal-title":"Intern Med"},{"issue":"9","key":"9335_CR42","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1038\/bjc.2015.120","volume":"112","author":"T Kalsi","year":"2015","unstructured":"Kalsi T, Babic-Illman G, Ross PJ, Maisey NR, Hughes S, Fields P et al (2015) The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people. Br J Cancer 112(9):1435\u20131444. https:\/\/doi.org\/10.1038\/bjc.2015.120","journal-title":"Br J Cancer"},{"key":"9335_CR43","doi-asserted-by":"publisher","unstructured":"Tarchand GR, Morrison V, Klein MA, Watkins E (2021) Use of comprehensive geriatric assessment in oncology patients to guide treatment decisions and predict chemotherapy toxicity. Fed Pract 38(Suppl 2):S22\u2013S28. https:\/\/doi.org\/10.12788\/fp.0128","DOI":"10.12788\/fp.0128"},{"issue":"1","key":"9335_CR44","doi-asserted-by":"publisher","first-page":"20","DOI":"10.7326\/M13-2231","volume":"161","author":"JC Weeks","year":"2014","unstructured":"Weeks JC, Uno H, Taback N, Ting G, Cronin A, D\u2019Amico TA et al (2014) Interinstitutional variation in management decisions for treatment of 4 common types of cancer: a multi-institutional cohort study. Ann Intern Med 161(1):20\u201330. https:\/\/doi.org\/10.7326\/M13-2231","journal-title":"Ann Intern Med"},{"issue":"21","key":"9335_CR45","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1002\/cncr.29576","volume":"121","author":"JA Wolfson","year":"2015","unstructured":"Wolfson JA, Sun CL, Wyatt LP, Hurria A, Bhatia S (2015) Impact of care at comprehensive cancer centers on outcome: results from a population-based study. Cancer 121(21):3885\u20133893. https:\/\/doi.org\/10.1002\/cncr.29576","journal-title":"Cancer"},{"issue":"4","key":"9335_CR46","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP et al (2022) Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 386(4):351\u2013363. https:\/\/doi.org\/10.1056\/NEJMoa2115304","journal-title":"N Engl J Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09335-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09335-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09335-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T07:10:00Z","timestamp":1745305800000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09335-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["9335"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09335-7","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"2 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HA, AO, TK, and SY are members of the Department of Prevention of Diabetes and Lifestyle-related Diseases, which is a cooperative program between The University of Tokyo and Asahi Mutual Life Insurance Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"293"}}